$MDT

Remote patient monitoring market projected to grow from $36.6B (2026) to $164.5B (2035) at 18.18% annual growth, driven by chronic disease prevalence and aging populations.

Orchestra BioMed will present at two major healthcare investor conferences in March 2026, engaging with institutional investors on strategy and clinical progress.

Rigid endoscopes market to grow from $7.36B to $11.52B by 2033, driven by minimally invasive surgery demand and technological advances in imaging capabilities.

Medtronic beat Q3 sales estimates at $9.02B with 8.7% growth, reaffirming full-year guidance. Strong cardiovascular and diabetes segments drove performance despite stock decline.

Hemostasis products market expected to grow from $1.94B to $3.28B by 2035, driven by increased surgeries and trauma cases requiring advanced bleeding control solutions.

Pulmonary artery catheter market projected to grow from $1.23B to $1.97B by 2035, driven by rising cardiovascular disease and expanding critical care infrastructure globally.

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.

Inflation cooled to 2.4%, steadying markets amid mixed earnings. Tech stocks showed divergence as investors reassess AI disruption timing.

Medtronic received FDA clearance for its Stealth AXiS spine surgery navigation system with real-time tracking technology, reducing need for intraoperative imaging and radiation exposure during procedures.